Company intelligence / Profile preview

Anterios, Inc.

New York, New York, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Anterios developed a proprietary needle-free topical delivery system for botulinum toxin and advanced several programs into Phase 2 clinical trials targeting crow’s feet, hyperhidrosis, and acne. Clinical studies demonstrated that their lead product ANT‑1207 was well tolerated and showed statistically significant efficacy in these indications. The company was acquired by Allergan in early 2016 to enhance Allergan's neurotoxin pipeline.[1][4][6]

Therapeutic areas: Dermatology
Modalities: Botulinum toxin (Type A)macromolecules[2][6]
Industry: Biotech

Drug pipeline

2 assets

ANT-1207

Phase 2

Indications: Primary axillary hyperhidrosis, Facial acne, Lateral canthal lines

1 more asset in the full pipeline.

Request access →

Partnerships

Allergan plc (acquirer)Eirion Therapeutics received non-exclusive rights to ANT‑1207 prior to the Allergan deal[4].

Beyond the preview

Go deeper on Anterios, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anterios, Inc..

Explore the full profile